During the premarket session this morning, shares of Windtree Therapeutics Inc. (WINT) are trading at $2.36, up 5.36%. Ending last trading session at $2.24, Windtree Therapeutics stock added 4.67%. Over the last 5 days, WINT shares have gained 4.67%, however, they are down -3.45% over the last one month.
The WINT stock price has dropped -58.82% over the last three months and is down -56.34 percent for the year. The stock was active for 0.44 million shares, which is less than the 50-day average daily trading volume of 0.5 million shares. WINT stock price could possibly be affected by recent developments, even though there have been no current news that could move it higher.
What has happened recently?
For patients with severe acute cardiovascular or pulmonary disorders, Windtree Therapeutics is advancing multiple late-stage interventions. Achieving a first in class treatment for acute heart failure and early cardiogenic shock in heart failure by using new clinical approaches, the WINT lab is developing a multi-asset franchise anchored on compounds that have the ability to activate SERCA2a.
An application for a prioritized Track One application was recently filed by Windtree Therapeutics with the United States Patent and Trademark Office (USPTO).
A patent was being sought based upon an application previously filed under the Patent Cooperation Treaty (PCT). WINT’s new istaroxime patent will receive examination and final disposition under this program within one year of being granted priority status, rather than the USPTO’s normal three-year examination period for non-prioritized applications.
What Istaroxime means for WINT?
Due to its importance, Windtree (WINT) is focusing on strengthening its patent estate since istaroxime is its lead pipeline asset. Istaroxime is being studied by WINT because of the larger unmet need for patients while making sure its patent estate has the greatest protection possible. As WINT plans, Istaroxime should be well prepared and protected in the commercialization stage once it successfully completes its clinical studies and receives regulatory approval.